Associations of Skeletal Muscle Mass and Body Mass Index With Clinical Outcomes in Autosomal Dominant Polycystic Kidney Disease: An Observational Study.
Dha Woon Im,Jiyun Jung,Miso Ha,Yon Su Kim,Kwon Wook Joo,Kook-Hwan Oh,Dong Ki Kim,Hajeong Lee,Seung Seok Han,Eunjeong Kang,Sehoon Park,Sung Joon Shin,Jangwook Lee,Jeongin Song,Yun Kyu Oh,Hayne Cho Park,Curie Ahn,Kyu-Beck Lee,Yeong Hoon Kim,Seungyeup Han,Yaerim Kim,Eun Hui Bae,Jae Yoon Park,Yong Chul Kim
{"title":"Associations of Skeletal Muscle Mass and Body Mass Index With Clinical Outcomes in Autosomal Dominant Polycystic Kidney Disease: An Observational Study.","authors":"Dha Woon Im,Jiyun Jung,Miso Ha,Yon Su Kim,Kwon Wook Joo,Kook-Hwan Oh,Dong Ki Kim,Hajeong Lee,Seung Seok Han,Eunjeong Kang,Sehoon Park,Sung Joon Shin,Jangwook Lee,Jeongin Song,Yun Kyu Oh,Hayne Cho Park,Curie Ahn,Kyu-Beck Lee,Yeong Hoon Kim,Seungyeup Han,Yaerim Kim,Eun Hui Bae,Jae Yoon Park,Yong Chul Kim","doi":"10.1053/j.ajkd.2025.09.004","DOIUrl":null,"url":null,"abstract":"RATIONALE & OBJECTIVE\r\nLow muscle mass is a risk factor for chronic kidney disease. In this study, we examined the relationship between muscle mass and mortality, as well as end-stage kidney disease (ESKD), in patients with autosomal dominant polycystic kidney disease (ADPKD).\r\n\r\nSTUDY DESIGN\r\nRetrospective cohort study.\r\n\r\nSETTING & PARTICIPANTS\r\n1,443 patients with ADPKD from eight tertiary-care hospitals in Korea between 2006 and 2020.\r\n\r\nEXPOSURES\r\nComputed tomography images were obtained at the third lumbar vertebra to measure the skeletal muscle area (SMA) using an artificial intelligence system. SMA indexed for w a height2 s classified as low-attenuation muscle area (LAMA) or normal-attenuation muscle area (NAMA) based on muscle quality.\r\n\r\nOUTCOMES\r\nAll-cause mortality and ESKD.\r\n\r\nANALYTICAL APPROACH\r\nCox proportional hazards regression, adjusted for sex, age, creatinine, glucose, and height-adjusted total kidney volume, was used to investigate the associations of muscle indices with all-cause mortality and ESKD. Subgroup analyses were conducted based on body mass index categories: low or normal (<25 kg/m2) and overweight or obese (≥25 kg/m2).\r\n\r\nRESULTS\r\nThe study population included more than half female patients, and the mean estimated glomerular filtration rate was 68.4 ml/min/1.73m2. Mean follow-up was 5.14 years. Greater SMA/height2 and NAMA/height2 were associated with a lower risk of mortality (HRs 0.58 (95% CI 0.39-0.88) and 0.55 (95% CI, 0.39-0.79), respectively). Greater NAMA/height2 was associated with a 26% lower ESKD incidence (0.74 (0.59,0.92), but a greater LAMA/height2 was associated with a lower ESKD incidence (HR 1.18, 95% CI 1.01-1.37). A higher NAMA/LAMA ratio was associated with a lower ESKD incidence (HR 0.74, 95% CI 0.60-0.92). Greater muscle mass was associated with a lower risk of mortality among overweight individuals and a lower risk of ESKD in underweight individuals.\r\n\r\nLIMITATIONS\r\nLack of details about muscle strength and performance.\r\n\r\nCONCLUSIONS\r\nAmong individuals with ADPKD, greater and higher-quality muscle mass were associated with lower risk of mortality and progression of CKD to ESKD.","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"104 1","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Kidney Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1053/j.ajkd.2025.09.004","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
RATIONALE & OBJECTIVE
Low muscle mass is a risk factor for chronic kidney disease. In this study, we examined the relationship between muscle mass and mortality, as well as end-stage kidney disease (ESKD), in patients with autosomal dominant polycystic kidney disease (ADPKD).
STUDY DESIGN
Retrospective cohort study.
SETTING & PARTICIPANTS
1,443 patients with ADPKD from eight tertiary-care hospitals in Korea between 2006 and 2020.
EXPOSURES
Computed tomography images were obtained at the third lumbar vertebra to measure the skeletal muscle area (SMA) using an artificial intelligence system. SMA indexed for w a height2 s classified as low-attenuation muscle area (LAMA) or normal-attenuation muscle area (NAMA) based on muscle quality.
OUTCOMES
All-cause mortality and ESKD.
ANALYTICAL APPROACH
Cox proportional hazards regression, adjusted for sex, age, creatinine, glucose, and height-adjusted total kidney volume, was used to investigate the associations of muscle indices with all-cause mortality and ESKD. Subgroup analyses were conducted based on body mass index categories: low or normal (<25 kg/m2) and overweight or obese (≥25 kg/m2).
RESULTS
The study population included more than half female patients, and the mean estimated glomerular filtration rate was 68.4 ml/min/1.73m2. Mean follow-up was 5.14 years. Greater SMA/height2 and NAMA/height2 were associated with a lower risk of mortality (HRs 0.58 (95% CI 0.39-0.88) and 0.55 (95% CI, 0.39-0.79), respectively). Greater NAMA/height2 was associated with a 26% lower ESKD incidence (0.74 (0.59,0.92), but a greater LAMA/height2 was associated with a lower ESKD incidence (HR 1.18, 95% CI 1.01-1.37). A higher NAMA/LAMA ratio was associated with a lower ESKD incidence (HR 0.74, 95% CI 0.60-0.92). Greater muscle mass was associated with a lower risk of mortality among overweight individuals and a lower risk of ESKD in underweight individuals.
LIMITATIONS
Lack of details about muscle strength and performance.
CONCLUSIONS
Among individuals with ADPKD, greater and higher-quality muscle mass were associated with lower risk of mortality and progression of CKD to ESKD.
期刊介绍:
The American Journal of Kidney Diseases (AJKD), the National Kidney Foundation's official journal, is globally recognized for its leadership in clinical nephrology content. Monthly, AJKD publishes original investigations on kidney diseases, hypertension, dialysis therapies, and kidney transplantation. Rigorous peer-review, statistical scrutiny, and a structured format characterize the publication process. Each issue includes case reports unveiling new diseases and potential therapeutic strategies.